Advicenne SACA Publishes 2025 Universal Registration Document

Advicenne SACA, a specialty pharmaceutical company listed on Euronext Growth Paris, has filed its 2025 Universal Registration Document with the French Autorité des Marchés Financiers (AMF). The filing was announced on 24 April 2026 by the company’s website and by the AMF’s official platform.

Contents of the Document

The Universal Registration Document includes:

  • The 2025 annual report
  • The management report
  • The Board of Directors’ report on corporate governance
  • The statutory auditors’ reports
  • A description of the share‑buyback program

These reports are available for download on Advicenne’s Investor Relations page and on the AMF’s website.

Company Background

Advicenne was founded in 2007 and focuses on developing innovative treatments for rare kidney diseases. Its flagship product, Sibnayal® (ADV7103), received marketing approval for distal renal tubular acidosis in the European Union and the United Kingdom. The product is currently in late‑stage development for cystinuria in Europe, and for both distal renal tubular acidosis and cystinuria in the United States and Canada.

The company is headquartered in Paris and has been listed on the Euronext Paris stock exchange since 2017. It transitioned to the Euronext Growth market on 30 March 2022.

Market Position

Advicenne’s market capitalization stands at €19.81 million. The company’s share price as of 22 April 2026 closed at €1.296. The 52‑week range for the share price is €1.104 (low) to €2.35 (high), reflecting recent volatility in the specialty‑pharma sector.

Investor Information

Investors can access the full Universal Registration Document and related filings through the following links:

For further inquiries, contacts are:

The release of the 2025 Universal Registration Document provides stakeholders with comprehensive financial, governance, and strategic information, supporting transparency and regulatory compliance for Advicenne SACA.